Bayer (BAYN) Given a €88.50 Price Target by Warburg Research Analysts

Bayer (FRA:BAYN) has been given a €88.50 ($102.91) price target by research analysts at Warburg Research in a note issued to investors on Thursday. The firm presently has a “buy” rating on the healthcare company’s stock. Warburg Research’s price objective would suggest a potential upside of 12.93% from the company’s previous close.

Other equities analysts have also issued reports about the stock. Baader Bank set a €140.00 ($162.79) price target on shares of Bayer and gave the stock a “buy” rating in a report on Wednesday, July 11th. UBS Group set a €130.00 ($151.16) price target on shares of Bayer and gave the stock a “buy” rating in a report on Tuesday, June 26th. Deutsche Bank set a €137.00 ($159.30) price target on shares of Bayer and gave the stock a “buy” rating in a report on Friday, June 22nd. Sanford C. Bernstein set a €120.00 ($139.53) price target on shares of Bayer and gave the stock a “buy” rating in a report on Thursday, June 21st. Finally, JPMorgan Chase & Co. set a €120.00 ($139.53) price target on shares of Bayer and gave the stock a “buy” rating in a report on Thursday, June 21st. Seven equities research analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of €98.80 ($114.88).

FRA BAYN opened at €78.37 ($91.13) on Thursday. Bayer has a 12-month low of €91.58 ($106.49) and a 12-month high of €123.82 ($143.98).

About Bayer

Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, Crop Science, and Animal Health segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.

Featured Story: Price to Earnings Ratio (PE), For Valuing Stocks

Analyst Recommendations for Bayer (FRA:BAYN)

Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply